- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02981277
Transcricoid Injection vs. Spray as You go Method for Local Anaesthesia During Bronchoscopy (CRISP)
Transcricoid Injection Versus Spray as You go Method for Local Anaesthesia During Flexible Bronchoscopy: A Randomised Controlled Trial
Flexible bronchoscopy is one of the most widely performed procedures for diagnosis of various bronchopulmonary diseases. Most patients tolerate the procedure well although cough is often reported as a distressing symptom. It is likely that the acceptance of bronchoscopy would be significantly improved with control of cough. Use of sedation during bronchoscopy has been reported to improve procedure tolerance. However, awake(no sedation) bronchoscopy is routinely performed at many centres including ours.
Topical lignocaine is administered during bronchoscopy for local anaesthesia. There is limited literature on the efficacy of transtracheal/transcricoid injection versus spray as you go method for lignocaine delivery to the airways during bronchoscopy. This study would help to determine the procedure comfort for the patient while using the transtracheal/transcricoid method vs the spray as you go method.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
For all patients meeting the inclusion criteria, the demographic profile including age, sex, weight, smoking history and the type of procedures performed during bronchoscopy shall be recorded. A written informed consent will be obtained from all participants. The patients who undergo flexible bronchoscopy would be randomised in a one is to one ratio either to transcricoid or spray as you go group. Prior to the bronchoscopy blood pressure, pulse rate, respiratory rate and pulse oximetry saturation will be recorded at the baseline Patients in both the groups shall be prepared in a similar fashion except for the initial route of lignocaine delivery.
During the procedure, 1.5 ml aliquots of 2% lignocaine solution will be delivered through the bronchoscope when using spray-as-you go technique. Patients in the transcricoid group shall initially receive 5 ml of 2% lignocaine solution instilled transtracheally along with two baseline 1.5 cc bronchial spray aliquots of lignocaine, and additional aliquots of 2% lignocaine using the spray as you go method. The total lignocaine dose during the procedure will be recorded. The patients would be monitored for any adverse effects throughout the procedure. The bronchoscopist doing the procedure will be provided 2 VAS charts to mark the severity of cough and overall procedure satisfaction. Cough count shall be noted.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
New Delhi, India, 110029
- All India Institute of medical Sciences
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Indication for diagnostic or therapeutic flexible bronchoscopy
- Age > 18 years
- Hemodynamic stability (defined as systolic BP >100 mm Hg and, <180 mm Hg).
Exclusion Criteria:
- Refusal of consent
- Known documented hypersensitivity to lignocaine
- Procedure performed under general anaesthesia
- Pregnancy
- Hypoxemia (oxygen saturation [by pulse oximetry] < 92% with Fio2 of ≥ 0.3
- Bronchoscopy done through endotracheal or tracheostomy tube
- Midline neck mass or thyroid enlargement making the identification of cricothyroid membrane difficult'
- Patients with central airway obstruction
- Patients with active ongoing hemoptysis
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Transcricoid
Lignocaine delivery using transcricoid injection
|
Lignocaine delivery using Transcricoid Injection
|
Active Comparator: Spray as You go
Lignocaine delivery using spray as you go method
|
Lignocaine delivery using Spray as you go method
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Cough count from bronchoscope introduction till reaching the carina
Time Frame: At study completion approximately 12 months
|
At study completion approximately 12 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Time from scope insertion to crossing the vocal cords
Time Frame: At study completion approximately 12 months
|
At study completion approximately 12 months
|
Overall procedure duration
Time Frame: At study completion approximately 12 months
|
At study completion approximately 12 months
|
Total Lignocaine dose
Time Frame: At study completion approximately 12 months
|
At study completion approximately 12 months
|
Operator rated overall procedure satisfaction
Time Frame: Through study completion, an average of 1 year
|
Through study completion, an average of 1 year
|
Collaborators and Investigators
Investigators
- Study Chair: Randeep Guleria, MD, DM, All India Institute of Medical Sciences, New Delhi
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Transcricoid RCT
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Disease
-
National Taipei University of Nursing and Health...TerminatedChronic Pulmonary Disease | Chronic Obstructive Pulmonary Disease Exacerbation | Chronic Obstructive Pulmonary Disease With ExacerbationTaiwan
-
Spire, Inc.ResMedCompletedSevere Chronic Obstructive Pulmonary Disease | Moderate Chronic Obstructive Pulmonary DiseaseUnited States
-
Kırıkkale UniversityRecruitingCOPD (Chronic Obstructive Pulmonary Disease)Turkey
-
Hopital FochAir Liquide SARecruitingChronic Obstructive Pulmonary Disease SevereFrance
-
Fundación para la Investigación del Hospital Clínico...Not yet recruitingCOPD, Chronic Obstructive Pulmonary DiseaseSpain
-
Canandaigua VA Medical CenterRecruitingChronic Obstructive Pulmonary Disease ModerateUnited States
-
Mylan Inc.Theravance BiopharmaCompletedChronic Obstructive Pulmonary Disease, COPDNew Zealand
-
Astellas Pharma Global Development, Inc.CytokineticsCompletedChronic Obstructive Pulmonary Disease (COPD)United States
-
AstraZenecaParexel International Ltd; Cognizant Technology Solution; Center for Information... and other collaboratorsCompletedChronic Obstructive Pulmonary Disease COPDUnited States, Canada, France, Russian Federation, Ukraine, Hungary, Bulgaria
-
University of ZurichNational Center of Cardiology and Internal Medicine named after academician...CompletedChronic Obstructive Pulmonary Disease (COPD)Kyrgyzstan
Clinical Trials on Transcricoid injection
-
All India Institute of Medical Sciences, New DelhiCompleted
-
National Taiwan University HospitalRecruitingOsteoarthritis (OA) of the KneeTaiwan
-
Jiangsu HengRui Medicine Co., Ltd.Completed
-
Jiangsu HengRui Medicine Co., Ltd.Completed
-
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Enrolling by invitationAdvanced Malignant TumorsChina
-
Jiangsu HengRui Medicine Co., Ltd.Not yet recruiting
-
Shengjing HospitalJiangsu HengRui Medicine Co., Ltd.Not yet recruitingER Positive/HER2 Low Breast CancerChina
-
Dalia Salah SaifUnknownRA - Rheumatoid ArthritisEgypt
-
Royan InstituteCompletedMyocardial InfarctionIran, Islamic Republic of
-
United States Naval Medical Center, San DiegoCEL-SCI CorporationTerminated